29th Mar 2007 14:30
Oxford Biomedica PLC29 March 2007 For Immediate Release 29 MARCH 2007 OXFORD BIOMEDICA: NOTICE OF ANNUAL GENERAL MEETING Oxford, UK - 29 March 2007: Oxford BioMedica (LSE: OXB), the leading genetherapy company, announces today that it will be holding its Annual GeneralMeeting on Thursday, 3 May 2007, 11.00am, at the offices of Morrison & FoersterMNP, CityPoint, One Ropemaker Street, London EC2Y 9AW. A notice of the 2007Annual General Meeting will be sent to shareholders on 2 April 2007. -Ends- For further information, please contact:Oxford BioMedica plc: Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Tel: +44 (0)20 7466 5000Buchanan CommunicationsScientific/Trade Press Enquiries: Gemma Price/ Holly Griffiths/ Katja Stout Tel: +44 (0)20 7268 3002 Northbank Communications Notes to editors 1. Oxford BioMedica Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in thedevelopment of novel gene-based therapeutics with a focus on oncology andneurotherapy. The Company was established in 1995 as a spin out from OxfordUniversity, and is listed on the London Stock Exchange. Oxford BioMedica has core expertise in gene delivery, as well as in-houseclinical, regulatory and manufacturing know-how. In oncology, the pipelineincludes TroVax(R), a cancer immunotherapy, which was recently licensed toSanofi-Aventis for global development and commercialisation. TroVax is in PhaseIII development for renal cancer and Sanofi-Aventis is implementing adevelopment plan for metastatic colorectal cancer. The recent acquisition ofOxxon Therapeutics adds a Phase II cancer immunotherapy for melanoma, HI-8 MEL(R), to the Company's pipeline. Other oncology product candidates include a genetherapy, MetXia(R), which is in Phase II development for pancreatic cancer, anda preclinical targeted antibody therapy, which is being developed incollaboration with Wyeth. In neurotherapy, the Company's lead product, ProSavin,is expected to enter clinical trials in Parkinson's disease in 2007. Thepreclinical pipeline includes gene-based products for vision loss, motor neurondisease and nerve repair. The acquisition Oxxon also provides a platform for thedevelopment of therapeutic vaccines for infectious diseases. The Company is underpinned by over 80 patent families, which represent one ofthe broadest patent estates in the field. The Company has a staff ofapproximately 75 split between its main facilities in Oxford and its whollyowned subsidiary, BioMedica Inc, in San Diego, California. In addition to theTroVax collaboration with Sanofi-Aventis and the targeted antibody therapycollaboration with Wyeth, Oxford BioMedica has corporate collaborations withIntervet, Sigma-Aldrich, Viragen, MolMed and Virxsys; and has licensedtechnology to a number of companies including Merck & Co, Biogen Idec,GlaxoSmithKline and Pfizer. Further information is available at www.oxfordbiomedica.co.uk This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Oxford Biomedica